Total compensation · 2025
$32.5M
$32,530,984 as reported in AbbVie Inc.'s proxy statement.
Names, titles and pay as reported by the company and its SEC filings, via Financial Modeling Prep. Reference only — nothing here is investment advice, and no affiliation with or endorsement by the people listed is implied.
| Year |
|---|
| Salary |
|---|
| Bonus |
|---|
| Stock awards |
|---|
| Option awards |
|---|
| Incentive plan |
|---|
| Other |
|---|
| Total |
|---|
| Filing |
|---|
| 2025 | $1.7M | $0 | $13.3M | $3.2M | $5.2M | $9.2M | $32.5M | SEC |
| 2024 | $1.6M | $0 | $7.9M | $1.9M | $4.6M | $2.5M | $18.5M | SEC |
| 2023 | $1.4M | $0 | $5.4M | $1.4M | $3M | $3.2M | $14.4M | SEC |
| 2022 | $1.3M | $0 | $4.7M | $1.1M | $2.5M | $159K | $9.8M | SEC |
| 2021 | $1.1M | $0 | $4.3M | $1.1M | $2.6M | $61.4K | $11.7M | SEC |
| 2020 | $1.1M | $0 | $5.4M | $1.3M | $2.1M | $49.4K | $13.5M | SEC |
| 2019 | $1.3M | $0 | $3.2M | $808.6K | $2.4M | $245.5K | $9.5M | SEC |
| 2018 | $553.7K | $0 | $724K | $173.7K | $950K | $717.5K | $3.1M | SEC |
| 2017 | $1M | $0 | $3.7M | $981K | $2M | $772.9K | $8.4M | SEC |
| 2016 | $961K | $0 | $3.4M | $850.9K | $1.6M | $476.6K | $7.2M | SEC |
| 2015 | $918.1K | $0 | $3.1M | $1M | $1.2M | $294.8K | $6.6M | SEC |
| 2014 | $503.8K | $1M | $7.7M | $734.9K | $1.2M | $394K | $11.5M | SEC |
AbbVie Options Price In a Sudden 5% Swing—What Investors Must Know Before Oct. 30
Oct 26, 2026https://247wallst.com/investing/2026/10/26/abbvie-options-price-in-a-sudden-5-swing-what-investors-must-know-before-oct-30/sentiment +0.40
U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI® (risankizumab-rzaa) for Adults With Moderately to Severely Active Crohn's Disease
Oct 23, 2026https://www.prnewswire.com/news-releases/us-fda-approves-subcutaneous-induction-regimen-for-abbvies-skyrizi-risankizumab-rzaa-for-adults-with-moderately-to-severely-active-crohns-disease-302918434.htmlsentiment +1.00
Great News for AbbVie Stock Investors
Oct 22, 2026https://www.fool.com/investing/2026/10/22/great-news-for-abbvie-stock-investors/sentiment +0.90
5 High-Yield Dividend Stocks That Could Turn October's Market Weakness Into Income
Oct 13, 2026https://247wallst.com/investing/2026/10/13/5-high-yield-dividend-stocks-that-could-turn-octobers-market-weakness-into-income/sentiment +0.20
Biotech's Rebound Reality: Surging M&A Deals Meet Deep Retail Skepticism
Oct 12, 2026https://www.etftrends.com/leveraged-inverse-content-hub/biotechs-rebound-reality-surging-ma-deals-meet-retail-skepticism/sentiment +0.50
AbbVie's Dividend Yield Is at Its Lowest Level Since 2018. Here's Why the Stock Is Still a Great Pick for Income Investors Anyway.
Oct 11, 2026https://www.fool.com/investing/2026/10/11/abbvies-dividend-yield-is-at-its-lowest-level-sinc/sentiment +0.90
